Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-28T18:34:32.133Z Has data issue: false hasContentIssue false
  • English
  • Français

Sexual adverse effects with new antidepressants

Published online by Cambridge University Press:  02 January 2018

Shameem Mir  and
David Taylor
Shameem Mir*
Affiliation:
Maudsley Hospital, Denmark Hill, London SE5 8AZ
David Taylor
Affiliation:
Maudsley Hospital, Denmark Hill, London SE5 8AZ
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Sexual dysfunction is a widely recognised adverse effect of many psychotropic agents. Older antidepressants such as monoamine oxidase inhibitors and tricycles, particularly clomipramine, are known to engender sexual adverse effects. In depression, this problem is exacerbated by the occurrence of impotence and lowered libido as part of depressive illness itself. We examined evidence relating to more recently introduced antidepressants: selective serotonin reuptake inhibitors, moclobemide, venlafaxine, nefazodone, mirtazapine and reboxetine. We reviewed published trials and case reports collated from searches of Medline, PsychLit and Micromedex from 1985 to December 1997, and contacted manufacturers of new antidepressants and requested information from them.

Type
Drug information quarterly
Information
Psychiatric Bulletin , Volume 22 , Issue 7 , July 1998 , pp. 438 - 441
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1998 The Royal College of Psychiatrists

References

Aizenberg, D., Zemishlany, Z. & Weizman, A. (1995) Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clinical Neuropharmacology, 18, 320–324.Google Scholar
Baldwin, D. & Johnson, N. (1995) Tolerability and safety of citalopram. Review of Contemporary Pharmacotherapy, 6, 315–325.Google Scholar
Balon, R. (1996) Intermittent amantadine for fluoxetine-induced anorgasmia. Journal of Sex and Marital Therapy, 22, 290–292.Google Scholar
Benazzi, F. (1995) Involuntary sperm emission with fluoxetine. Canadian Journal of Psychiatry, 40, 431.CrossRefGoogle ScholarPubMed
Berk, M. & Acton, M. (1997) Citalopram-associated clitoral priapism: a case series. International Clinical Psychopharmacology, 12, 121–122.CrossRefGoogle ScholarPubMed
Berzewski, H., Van Moffaert, M. & Gagiano, C. A. (1997) Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive episodes. European Neuropsychopharmacology, 7, S37–S47.Google Scholar
Charles, F., Weber, C. & Weber, S. S. (1993) Paroxetine: A selective serotonin reuptake inhibiting antidepressant. Annals of Pharmacotherapy, 27, 1212–1220.Google Scholar
Doogan, D. P. & Caillard, V. (1988) Sertraline: a new antidepressant. Journal of Clinical Psychiatry, 49, 46–51.Google Scholar
Dorevitch, A. & Davis, H. (1994) Fluvoxamine-associated sexual dysfunction. Annals of Pharmacotherapy, 28, 872–874.Google Scholar
Dubovsky, S. L. & Thomas, M. (1995) Serotonergic mechanisms and current future psychiatric practice. Journal of Clinical Psychiatry, 56 (suppl.), 38–48.Google ScholarPubMed
Gitlin, M. J. (1994) Psychotropic medications and their effects on sexual dysfunction: Diagnosis, biology, and treatment approaches. Journal of Clinical Psychiatry, 55, 406–413.Google ScholarPubMed
Hawley, C. & Smith, V. (1994) Review of a paper entitled “Effects of antidepressants on sexual function”. Medical Dialogue, 4, 1–4.Google Scholar
Herman, J. B., Brotman, A. W., Pollack, M. H., et al (1990) Fluoxetine-induced sexual dysfunction. Journal of Clinical Psychiatry, 51, 25–27.Google Scholar
Hong, S. L., Dong, H. S., Chan-Hyung, K., et al (1996) An open clinical trial of fluoxetine in the treatment of premature ejaculation. Journal of Clinical Psychopharmacology, 16, 379–382.Google Scholar
Jacobsen, F. M. (1992) Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. Journal of Clinical Psychiatry, 53, 119–122.Google Scholar
Lauerma, H. (1995) A case of moclobemide-induced hyperorgasmia. International Clinical Psychopharmacology, 10, 123–124.Google Scholar
Lauerma, H. (1996) Successful treatment of citalopram-induced anorgasmia by cyproheptadine. Acta Psychiatrica Scandinavica, 93, 69–70.Google Scholar
Mendels, J., Johnston, R., Mattes, J., et al (1993) Efficacy and safety of b.i.d. doses of venlafaxine in a dose response study. Psychopharmacology Bulletin, 29, 169–174.Google Scholar
Michael, A. & Owen, A. (1997) Venlafaxine-induced increased libido and spontaneous erections. British Journal of Psychiatry, 170, 193.Google Scholar
Montgomery, S. A. (1995) Safety of mirtazepine: a review. International Clinical Psychopharmacology, 4, 37–45.CrossRefGoogle Scholar
Morris, P. L. (1991) Fluoxetine and orgasmic sexual experiences. International Journal of Psychiatry in Medicine, 21, 379–382.Google Scholar
Mucci, M. (1997) Reboxetine: a review of antidepressant tolerability. Journal of Psychopharmacology, 11, 533–537.Google Scholar
Murray, M. J. & Hooberman, D. (1993) Fluoxetine and prolonged erection. American Journal of Psychiatry, 150, 167–168.Google Scholar
Nelson, E. B., Keck, P. E. Jr & McElroy, S. L. (1997) Resolution of fluoxetine-induced sexual dysfunction with the 5-HT3 antagonist granisitron. Journal of Clinical Psychiatry, 58, 496–497.CrossRefGoogle Scholar
Philipp, M., Kohnen, R. & Benkert, O. (1993) A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction. International Clinical Psychopharmacology, 7, 149–153.CrossRefGoogle ScholarPubMed
Preskorn, S. H. (1995) Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. Journal of Clinical Psychiatry, 56, 12–21.Google Scholar
Reynolds, R. D. (1997) Sertraline-induced anorgasmia treated with intermittent nefazodone (letter). Journal of Clinical Psychiatry, 58, 89.Google Scholar
Rothschild, A. J. (1995) Selective serotonin reuptake inhibitor - induced sexual dysfunction: efficacy of a drug holiday. American Journal of Psychiatry, 152, 1514–1516.Google Scholar
Shrivastava, R. K., Shrivastava, S., Overweg, N., et al (1995) Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology, 15, 83–84.Google Scholar
Waldinger, M. D. (1996) Use of psychoactive agents in the treatment of sexual dysfunction. CNS Drugs, 6, 204–216.Google Scholar
Waldinger, M. D., Hengreveld, M. W. & Zwinderman, A. H. (1997) Ejaculation-retarding properties of paroxetine in patients with primary premature ejaculation: a double-blind, randomized, dose response study. British Journal of Urology, 79, 592–595.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.